StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) stock

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.87−0.03 (-0.77%)

Close on Nov 17, 2026Market cap $160.98MP/E 0.9Yield 6.46%

Oramed Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Oramed Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$5.21M. For fiscal 2025 it was -$9.15M. The highest annual figure on record is $4.66M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.15M–
FY2024Dec 31, 2024-$8.41M–
FY2023Dec 31, 2023-$10.30M–
FY2021Aug 31, 2021-$21.18M–
FY2020Aug 31, 2020-$12.44M–
FY2019Aug 31, 2019-$12.94M–
FY2018Aug 31, 2018-$14.66M–
FY2017Aug 31, 2017-$5.83M-225.3%
FY2016Aug 31, 2016$4.66M–
FY2015Aug 31, 2015-$4.95M–
FY2014Aug 31, 2014-$4.07M–
FY2013Aug 31, 2013-$3.40M–
FY2012Aug 31, 2012-$2.30M–
FY2011Aug 31, 2011-$1.71M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$200.00K–
Q1 FY2026CQ1 2026Mar 31, 2026-$2.92M–
Q4 FY2025CQ4 2025Dec 31, 2025-$466.00K–
Q3 FY2025CQ3 2025Sep 30, 2025-$1.63M–
Q2 FY2025CQ2 2025Jun 30, 2025-$3.54M-270.3%
Q1 FY2025CQ1 2025Mar 31, 2025-$3.52M–
Q4 FY2024CQ4 2024Dec 31, 2024-$1.91M–
Q3 FY2024CQ3 2024Sep 30, 2024-$7.10M–
Q2 FY2024CQ2 2024Jun 30, 2024$2.08M–
Q1 FY2024CQ1 2024Mar 31, 2024-$1.48M–
Q4 FY2023CQ4 2023Dec 31, 2023-$1.42M–
Q3 FY2023CQ3 2023Sep 30, 2023-$694.00K–
Q2 FY2023CQ2 2023Jun 30, 2023-$2.63M–
Q1 FY2023CQ1 2023Mar 31, 2023-$5.55M–
Q4 FY2021CQ3 2021Aug 31, 2021-$6.14M–
Q3 FY2021CQ2 2021May 31, 2021-$5.64M–
Q2 FY2021CQ1 2021Feb 28, 2021-$3.25M–
Q1 FY2021CQ4 2020Nov 30, 2020-$6.15M–
Q4 FY2020CQ3 2020Aug 31, 2020-$2.46M–
Q3 FY2020CQ2 2020May 31, 2020-$3.36M–
Q2 FY2020CQ1 2020Feb 29, 2020-$3.63M–
Q1 FY2020CQ4 2019Nov 30, 2019-$3.00M–
Q4 FY2019CQ3 2019Aug 31, 2019-$3.27M–
Q3 FY2019CQ2 2019May 31, 2019-$3.66M–
Q4 FY2018CQ3 2018Aug 31, 2018-$4.65M–
Q3 FY2018CQ2 2018May 31, 2018-$3.81M–
Q2 FY2018CQ1 2018Feb 28, 2018-$3.48M–
Q1 FY2018CQ4 2017Nov 30, 2017-$2.73M-282.1%
Q4 FY2017CQ3 2017Aug 31, 2017-$2.05M-130.1%
Q3 FY2017CQ2 2017May 31, 2017-$2.36M–
Q2 FY2017CQ1 2017Feb 28, 2017-$2.93M-225.9%
Q1 FY2017CQ4 2016Nov 30, 2016$1.50M–
Q4 FY2016CQ3 2016Aug 31, 2016$6.80M–
Q3 FY2016CQ2 2016May 31, 2016-$2.23M–
Q2 FY2016CQ1 2016Feb 29, 2016$2.32M–
Q1 FY2016CQ4 2015Nov 30, 2015-$2.25M–
Q4 FY2015CQ3 2015Aug 31, 2015-$1.03M–
Q3 FY2015CQ2 2015May 31, 2015-$914.00K–
Q2 FY2015CQ1 2015Feb 28, 2015-$1.60M–

More Oramed Pharmaceuticals figures

See a number that looks wrong?